← Back to Clinical Trials
Recruiting NCT07392411

NCT07392411 Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07392411
Status Recruiting
Phase
Sponsor Beijing Tiantan Hospital
Condition Parkinson's Disease
Study Type OBSERVATIONAL
Enrollment 720 participants
Start Date 2023-07-25
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 15 Years
Max Age 75 Years
Study Type OBSERVATIONAL
Interventions
video recording

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 720 participants in total. It began in 2023-07-25 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This research employs AI to analyze facial expressions and speech patterns, aiming to develop new digital tools for diagnosing and differentiating Parkinson's disease and similar disorders.

Eligibility Criteria

Inclusion Criteria: 1. Inclusion Criteria for Parkinson's Disease (PD) Group: (1) Diagnostic Criteria: Meet the diagnostic criteria for Parkinson's disease established by the Movement Disorder Society (MDS) in 2015. (2) Age Range: 18-75 years old. (3) Disease Severity: Early-stage PD: Hoehn-Yahr score ≤ 2.5 points. Mid-to-late-stage PD: Hoehn-Yahr score 2.5-5 points. (4) Consent for Data Collection: Willing to undergo facial expression video and speech audio recording. (5) Informed Consent: Signed informed consent form. 2. Inclusion Criteria for Parkinson's Plus Syndromes (MSA-P, PSP) Group: (1) Age Range: 18-75 years old. (2) Diagnostic Criteria: MSA patients must meet the diagnostic criteria established by the \[Chinese Expert Consensus on the Diagnosis of Multiple System Atrophy, 2017\]. PSP patients must meet the diagnostic criteria established by the \[Chinese Clinical Diagnostic Criteria for Progressive Supranuclear Palsy, 2016 Edition\]. (3) Consent for Data Collection: Willing to undergo facial expression video and speech audio recording. (4) Informed Consent: Signed informed consent form. Exclusion Criteria: 1. History of cerebrovascular disease, head trauma, hydrocephalus, brain tumors, or intracranial surgery. 2. Presence of metal implants, cardiac pacemakers, or other metallic foreign bodies (applies to PD patients). 3. Severe dyskinesia in PD patients that would compromise cooperation with video/audio recording. 4. Mini-Mental State Examination (MMSE) score ≤ 24 points.

Contact & Investigator

Central Contact

Lingyan Ma, M.D.

✉ Jennifer_MLY@163.com

📞 +8613520873987

Frequently Asked Questions

Who can join the NCT07392411 clinical trial?

This trial is open to participants of all sexes, aged 15 Years or older, up to 75 Years, studying Parkinson's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07392411 currently recruiting?

Yes, NCT07392411 is actively recruiting participants. Contact the research team at Jennifer_MLY@163.com for enrollment information.

Where is the NCT07392411 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT07392411 clinical trial?

NCT07392411 is sponsored by Beijing Tiantan Hospital. The trial plans to enroll 720 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology